Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Joji Mori
Observed name:
J. Mori
Institution:
Eli Lilly (Japan)
Observed institutions:
Eli Lilly (Japan),
Ono Pharmaceutical (Japan),
The University of Osaka
ORCID:
0000-0002-6545-464X
Observed ORCID:
0000-0002-6545-464X
OpenAlex ID:
A5085618006
Phase 1 study of abemaciclib, an inhibitor of CDK 4 and 6, as a single agent for Japanese patients with advanced cancer
2016
·
Yutaka Fujiwara
, Kenji Tamura
, et al.
·
Cancer Chemotherapy and Pharmacology
·
66
A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of the Rivastigmine Patch in Japanese Patients with Alzheimer’s Disease
2011
·
Yu Nakamura
, Yukimichi Imai
, et al.
·
Dementia and Geriatric Cognitive Disorders Extra
·
57
PDF
Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer
2021
·
Masato Takahashi
, Eriko Tokunaga
, et al.
·
Breast Cancer
·
33
PDF
A phase 1 study of crenigacestat (LY3039478), the Notch inhibitor, in Japanese patients with advanced solid tumors
2020
·
Toshihiko Doi
, Masaomi Tajimi
, et al.
·
Investigational New Drugs
·
31
PDF
Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy
2021
·
Kenichi Inoue
, Norikazu Masuda
, et al.
·
Breast Cancer
·
25
PDF
Impact of the quality of resected thyroid cancer tissue sample on next‐generation sequencing testing
2024
·
Kanako C. Hatanaka
, Kenichi Nakamura
, et al.
·
Pathology International
·
10
PDF
Phase 1 study of olaratumab plus doxorubicin in Japanese patients with advanced soft‐tissue sarcoma
2018
·
Kan Yonemori
, Makoto Kodaira
, et al.
·
Cancer Science
·
6
PDF
A powerful test for Balaam's design
2015
·
Joji Mori
, Yutaka Kano
·
Pharmaceutical Statistics
·
5
[Efficacy and Safety Analysis of Selpercatinib in Patients with RET Fusion-Positive Non-Small Cell Lung Cancer-Results from the Japanese Subset of a Global Phase 1/2 Study].
2022
·
Makoto Nishio
, Yuichiro Ohe
, et al.
·
PubMed
·
4
314 Phase 1 study of abemaciclib, a CDK 4 and 6 inhibitor, as a single agent for Japanese patients with advanced cancer
2015
·
S. Kondo
, N. Yamamoto
, et al.
·
European Journal of Cancer
·
3
Clinical Impact of a Shortened Infusion Duration of Ramucirumab in Japanese Patients -A Model-Based Approach.
2021
·
Seiichiro Mitani
, Yucherng Chen
, et al.
·
PubMed
·
2
Real-World Safety and Effectiveness of Lasmiditan in Patients with Migraine: A Post-Marketing Observational Study in Japan
2026
·
Naoko Sanno
, Kevin Y. Urayama
, et al.
·
Neurology and Therapy
·
1
PDF
308P Imlunestrant (imlu), as monotherapy and combined with abemaciclib (abema), in East Asian (EA) patients (pts) with advanced breast cancer (ABC): Results from the phase III EMBER-3 trial
2025
·
S-B. Kim
, J. Sohn
, et al.
·
ESMO Open
·
1
Item Response Theory Using a Finite Mixture of Logistic Models With Item-specific Mixing Weights
2013
·
Joji Mori
, Yutaka Kano
·
Journal of the Japanese Society of Computational Statistics
·
1
PDF
Safety and effectiveness of selpercatinib in patients with RET fusion-positive non-small cell lung cancer in real-world clinical practice: a postmarketing study in Japan
2025
·
Yucherng Chen
, Joji Mori
, et al.
·
Japanese Journal of Clinical Oncology
Latent class models for medical diagnostic tests in multicenter trials
2013
·
Joji Mori
, Yutaka Kano
, et al.
·
Statistics in Medicine
P4‐232: A 24‐week, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy, safety, and tolerability of the rivastigmine patch in Japanese patients with Alzheimer's disease
2011
·
Yu Nakamura
, Yukimichi Imai
, et al.
·
Alzheimer s & Dementia
Show more works
View as search
Works count:
17
Citation count:
245
H-index:
6
I10-index:
6
Year
Topic
Type